Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Allovir, Inc. (ALVR) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Quarterly results
Docs: "AlloVir Reports Second Quarter 2023 Financial Results"
05/16/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
05/04/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"AlloVir Reports First Quarter 2023 Financial Results"
02/23/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"AlloVir Appoints Derek Adams, Ph.D., to Board of Directors"
01/09/2023 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"AlloVir Announces Plans to Complete Enrollment in Three Phase 3 Posoleucel Studies in 2023"
11/21/2022 8-K Quarterly results
11/03/2022 8-K Quarterly results
08/04/2022 8-K Quarterly results
07/27/2022 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Opinion of Goodwin Procter LLP",
"Securities Purchase Agreement, by and between AlloVir, Inc. and the investors identified therein",
"AlloVir Announces $126.6 Million Registered Direct Offering"
05/19/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
03/31/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"AlloVir Appoints Shawn Tomasello to Its Board of Directors"
02/10/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"AlloVir Reports Full-Year 2021 Financial Results and 2022 Outlook"
01/10/2022 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: "AlloVir, Inc. corporate presentation",
"AlloVir, Inc. corporate presentation"
12/17/2021 8-K Quarterly results
12/13/2021 8-K Quarterly results
11/15/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "AlloVir, Inc. corporate presentation"
11/05/2021 8-K Quarterly results
Docs: "AlloVir Reports Third Quarter 2021 Financial Results"
09/13/2021 8-K Quarterly results
08/06/2021 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : August 6, 2021 ALLOVIR, INC. Delaware 001-39409 83-1971007 AlloVir, Inc. 139 Main Street, Suite 500 Cambridge, Massachusetts 02142 433-2605 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant t...",
"AlloVir Reports Second Quarter 2021 Financial Results"
07/28/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Consulting Agreement by and between AlloVir, Inc. and David Hallal, effective as of July 22, 2021",
"Consulting Agreement by and between AlloVir, Inc. and David Hallal, effective as of July 22, 2021"
05/25/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
03/22/2021 8-K Quarterly results
02/11/2021 8-K Quarterly results
01/14/2021 8-K Quarterly results
12/17/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : December 17, 2020 ALLOVIR, INC. Delaware 001-39409 83-1971007 AlloVir, Inc. 139 Main Street, Suite 500 Cambridge, Massachusetts 02142 433-2605 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuan...",
"AlloVir Announces FDA Clearance of Investigational New Drug Application for ALVR106, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T Cell Therapy Targeting Four Devastating Respiratory Viruses"
12/07/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : December 7, 2020 ALLOVIR, INC. Delaware 001-39409 83-1971007 AlloVir, Inc. 139 Main Street, Suite 500 Cambridge, Massachusetts 02142 433-2605 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant...",
"Positive Phase 2 Proof-of-Concept Data for Viralym-M and Burden of Disease Data Presented in Oral Presentations at the 62nd American Society of Hematology Annual Meeting"
12/07/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : December 5, 2020 ALLOVIR, INC. Delaware 001-39409 83-1971007 AlloVir, Inc. 139 Main Street, Suite 500 Cambridge, Massachusetts 02142 433-2605 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐   Written communications pursuant to Rule 425 under the Securities Act ☐   Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐   Pre-commencement communications pursuant to Rule 14d-2 under the Exc...",
"Preclinical Data Demonstrate Anti-Viral Activity of AlloVir's ALVR109, an Allogeneic, Off-the-Shelf SARS-CoV-2 Specific T Cell Therapy"
12/03/2020 8-K Entry into a Material Definitive Agreement
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 30, 2020 ALLOVIR, INC. Delaware 001-39409 83-1971007 AlloVir, Inc. 139 Main Street, Suite 500 Cambridge, Massachusetts 02142 433-2605 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuan..."
11/10/2020 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 10, 2020 ALLOVIR, INC. Delaware 001-39409 83-1971007 AlloVir, Inc. 139 Main Street, Suite 500 Cambridge, Massachusetts 02142 433-2605 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuan...",
"AlloVir Reports Third Quarter 2020 Financial Results"
09/17/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : September 17, 2020 ALLOVIR, INC. Delaware 001-39409 83-1971007 AlloVir, Inc. 139 Main Street, Suite 500 Cambridge, Massachusetts 02142 433-2605 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursua...",
"AlloVir Announces the FDA Clearance of Investigational New Drug Application for ALVR109 for the Treatment of High-Risk COVID-19 Patients"
09/02/2020 8-K Quarterly results
08/03/2020 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy